“Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce/stop transmission,” the company said in a statement. The company aims to conduct clinical trials on 5,000 healthy people at nine locations in the country. If approved as a booster dose, the intranasal vaccine will be given six months after the second dose,” the company said.
